Alkermes (ALKS)
News
| May 24 | Bull Case for Mannkind Fool |
| May 18 | Revenues Skyrocket at Merged Alkermes |
| May 18 | ALKERMES PLC. Files SEC form 10-K, Annual Report |
| May 18 | UPDATE: Goldman Sachs Reiterates Neutral Rating, Lowers PT for Alkermes Benzinga |
| May 18 | New Star Analyst Rankings for Alkermes plc |
| May 17 | $ALKS Mentioned more than normal on StockTwits - Currently at 12 x average daily social activity by TradeIdeasQuant |
| May 17 | $znga holds 8.25 sup. Compared to the rest of the stocks I watched that's a success $aapl $kors $thld $alks $siri $kog $wynn by oneismany |
| May 17 | $aapl out for 3.5% loss, should of put my stop in but forgot too.... $znga may be in for another leg higher $alks bad $thld consolidating by oneismany |
| May 17 | News related to $ALKS, currently -6.1% since open: 'Alkermes takes bigger 4Q loss after Elan deal' http://stks.co/3sPQ by TradeBot |
| May 17 | Alkermes takes bigger 4Q loss after Elan deal |
| May 17 | Listen to $ALKS Q4 2012 earnings call - live at 08:30 AM, ondemand after - http://stks.co/3rwi by earningscast |
Profile
Exchange: NASDAQGS Sector: Healthcare Industry: Drug Delivery & Accessories
Alkermes plc is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to develop innovative medicines that improve patient outcomes. The company has a diversified portfolio of more than 20 commercial drug products and a substantial clinical pipeline of product candidates that address central nervous system (CNS) disorders such as addiction, schizophrenia and depression. The company is the result of a merger in September 2011 between Alkermes, Inc. and Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Elan Corporation, plc. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts and manufacturing facilities in Athlone, Ireland; Gainesville, Georgia; and Wilmington, Ohio. The company was founded in 1987.
1 Year Total Return Performance
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Alkermes is down 11.12% over the last year vs S&P 500 Total Return up 1.62%, Elan Corporation up 52.29%, and PetMed Express up 0.00%.
- ALKS Total Returns
- ^SPXTR Total Returns
- ELN Total Returns
- PETS Total Returns
Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these ALKS related companies
Pro Strategies Featuring ALKS
Did Alkermes make it into our Pro Portfolio Strategies?
ALKS Charts
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Other ALKS Resources
- Company Website
- Wiki Page
- Investor Relations
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
- Technical Charts Chart.ly
- Trading Ideas Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ALKS | 16.14 | +0.19 | +1.19% | 2.092B |
| ALK | 33.96 | +0.12 | +0.35% | 2.422B |
| ALIM | 2.63 | +0.00 | +0.00% | 82.66M |
| ALGT | 64.04 | -0.21 | -0.33% | 1.222B |
| ALG | 30.55 | -0.06 | -0.20% | 362.93M |
| ALEX | 50.87 | -0.34 | -0.66% | 2.130B |
| ALE | 38.80 | +0.10 | +0.26% | 1.474B |
| ALD | 50.08 | -0.03 | -0.06% | |
| ALCO | 24.62 | -0.31 | -1.24% | 180.96M |
| ALC | 14.57 | -0.13 | -0.88% | 334.67M |
